Eli Lilly Sets Up R&D Center In China
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly recently set up its China R&D center in Shanghai as a focal point for the company's innovation network. The facility aims to seek, promote and manage collaboration with local companies and academic institutions. Sited at Zhangjiang Hi-Tech Park which houses several of Lilly's current partners, the China team will be responsible for managing outsourced, risk-sharing R&D projects, mutual transfer of candidate drugs and technology, as well as venture capital investment in healthcare across Greater China. The move shows Lilly's stand of deepening investment in China and its growing confidence in local companies' creativity, efficiency and capability in biopharmaceutical research. (Click here for more - Chinese Language)